个人简介

Bruno Gander was appointed senior scientist at the Institute of Pharmaceutical Sciences at ETH Zurich (group of Galenical Pharmacy) in 1995, and was awarded the title of a Professor in 2005. Bruno Gander was born on February 27, 1955, in CH-Immensee. He studied pharmacy at the ETH Zurich (1975-1981). Thereafter, he did an industrial training in galenical research and development at Zyma S.A. (CH-Nyon). He earned his Ph.D. at the University of Geneva (1982-1986) under Prof. Eric Doelker, Prof. Robert Gurny, and Prof. Nicholas A. Peppas); part of the Ph.D.-work was done at the Department of Chemical Engineering at the Purdue University (West Lafayette, IN, USA). He worked 1986-1987 as a postdoc under Prof. N.B. Graham at the Department for Pure and Applied Chemistry at the University of Strathclyde (Glasgow, U.K.). Prior to his appointment as head-assistant at the Institute of Pharmaceutical Sciences at ETH Zurich in 1989, he held the position of a head-assistant in Galenical Pharmacy at the University of Geneva. He was appointed senior scientist in 1995 and completed his habilitation in 1999 in pharmaceutical technology and dosage forms. Honours Year Distinction 2013 Fellow of the Swiss Society of Pharmaceutical Sciences Additional information Bruno Gander is editor of the European Journal of Pharmaceutical Sciences and member of the Editorial board of several other scientific journals. He chairs the expert group Galenical Pharmacy of the Swiss Federal Pharmacopoeia Commission and is a member of the Federal Commission for Education of Medicinal Professions (MEBEKO). He also dedicates efforts to promote continuous education of public and hospital pharmacists (Pharmaceutical Society Zurich; Biotech-Forum) and coordinates the ETH Master study program in Medicinal and Industrial Pharmaceutical Sciences (MIPS).

研究领域

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Galenical Pharmacy

Research area: Biodegradable delivery systems for drugs and antigens. The therapeutic areas of interest for these delivery systems encompass infections, cancer, peripheral nerve guidance and regeneration, and vaccination with established and newer immunogens and immune response enhancers.